key: cord-0891167-4nv059p1
authors: Acharya, Rituparna
title: Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate
date: 2020-07-09
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110084
sha: aca2776d2b728f099dac06c636e82deb550dccfc
doc_id: 891167
cord_uid: 4nv059p1

COVID-19 is the pandemic outbreak that is caused by SARS-CoV-2 virus from December, 2019. Human race do not know the curative measure of this devastating disease. In today’s era of nanotechnology, it may use its knowledge to develop molecular vaccine to combat this disease. In this article we are intended to propose a hypothesis on the development of a vaccine that is molecular in nature to work against COVID-19. The nanoconjugate may comprise with the inorganic nanoparticle layered double hydroxide intercalated with shRNA-plasmid that have a sequence targeting towards the viral genome or viral mRNA. This nanoconjugate may be used as a nasal spray to deliver the shRNA-plasmid to the target site. The nanoconjugate will have several advantages such as they are biocompatible, they forms as stable knockdown to the target cells and they are stable in the nasal mucosa.

1 Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate Rituparna Acharya School of Bio-Science and Engineering, Jadavpur University, Kolkata 700 032, India Author for correspondence (rituparnaacharya@rediffmail.com)

COVID-19 is the pandemic outbreak that is caused by SARS-CoV-2 virus from December, 2019. Human race do not know the curative measure of this devastating disease. In today's era of nanotechnology, it may use its knowledge to develop molecular vaccine to combat this disease.

In this article we are intended to propose a hypothesis on the development of a vaccine that is molecular in nature to work against COVID-19. The nanoconjugate may comprise with the inorganic nanoparticle layered double hydroxide intercalated with shRNA-plasmid that have a sequence targeting towards the viral genome or viral mRNA. This nanoconjugate may be used as a nasal spray to deliver the shRNA-plasmid to the target site. The nanoconjugate will have several advantages such as they are biocompatible, they forms as stable knockdown to the target cells and they are stable in the nasal mucosa.

Keywords: COVID-19; SARS-CoV-2; shRNA; LDH; plasmid; gel mobility assay; XRD; shRNAs are nothing but the short hairpin RNA molecules that have special power of gene silencing with target sequence (3). shRNAs may be delivered to the target cells by the help of nanoparticles. Nanoparticles are small particles with size smaller than 100nm. They may be of different types such as inorganic, organic or polymeric nanoparticles. Layered double hydroxide (LDH) is a type of inorganic nanoparticle that is highly biocompatible, and has the ability to protect the shRNA from enzymatic degradation (4). LDH have layers in their nano structure and they intercalate the shRNA-plasmid within those layers. Due to their cationic nature they are easily internalized by the cell as the cell membrane have anionic property (5) . After the uptake of this nanoconjugate the shRNA-plasmid is incorporated within the genome of the cell and start transcribing the pre-shRNA. This pre-shRNA is transported to the cytoplasm from the nucleus by In this article we are intended to give a hypothesis on the production of molecular vaccine that may protect our body from COVID-19.

COVID -19 is a disease condition that is incurable in today's world. Invention of a vaccine is the need of the hour. In this era of nanotechnology we may use nanoparticles to develop a molecular vaccine for this disease condition. We may use layered double hydroxide as a nanoparticle in conjugation with shRNAs with specific sequence that may target the viral RNA to degrade them as soon as they enter within the cell. The conjugate may be used as a nasal spray to the probable effectible location as a prophylaxis.

The synthesis method of LDH nanoparticle is by co-precipitation method with Mg:Al molar ratio X-ray diffraction (XRD), particle size and TG/DTA analysis may be performed for the characterization of the LDH nanoparticle.

For the isolation of plasmid shRNA 2.5% LB broth medium should be autoclaved and ampicillin or any other antibiotic should be added upto a final concentration of 100μg/ml depending upon the antibiotic resistance of the E. coli purchased. Then the E. coli transfected with Lentiviral shRNA-plasmid should be added and cultured overnight at 37 °C under vigorous shaking. Next morning the plasmid should be isolated using any plasmid isolation kit available in the market and should be isolated according to the manufacturer's protocol, followed by the quantification of plasmid by measuring absorption of the solution at 260 nm, and should be characterized using the gel retardation assay.

A suspension of the LDH nanoparticles should be prepared using DNase-free water with a final concentration of 10 µg/µl. The suspension should be sonicated for 10minutes before making the mixture shRNA-plasmid at the mass ratios of shRNA-plasmid: LDH, 1:25, 1:50, 1:75 and 1:100, followed by incubation at different time points, such as 30min or 45min or 60 min at 37 °C for the preparation of the final intercalate of shRNA-plasmid-LDH nanoconjugate. The intercalation should be checked using 1% agarose gel containing ethidium bromide that should be loaded with 0.1 μg of the shRNA-plasmid. The DNA loading buffer should be used for electrophoresis in TBE buffer containing ethidium bromide at 80V for approximately 45 mins. The bare plasmid should be used as a control and the final gel images should be captured using a UV transilluminator (5, 7).

Currently, there is no such vaccine for COVID-19 although some are in clinical trials. The vaccines available in today's world are mainly that activates the immune system but molecular vaccines have a separate principle. Molecular vaccines use the shRNA-plasmids for silencing the 5 viral RNA before it starts to produce viral protein molecules. Molecular vaccines have an advantage over other currently available vaccines as they may be used as a treatment module for viral infections as well. Moreover, if one can choose a target site on the viral genome that is common to other viruses while selecting the shRNA sequence then, that nanoconjugate will become the common vaccine for wide variety of viruses. Further, the use of shRNA makes a stable knockdown of the cell line so it have better efficacy than small interfering RNAs (siRNAs) (8) . These advantages of the molecular vaccine may become the most upcoming new modality of vaccination in today's world.

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

57 -Coronaviruses

A system for stable expression of short interfering RNAs in mammalian cells

The recent progresses in shRNA-nanoparticle conjugate as a therapeutic approach

Intercalation of shRNA-plasmid in Mg-Al layered double hydroxide nanoparticles and its cellular internalization for possible treatment of neurodegenerative diseases

Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells

An in vitro comparative study of layered-double hydroxide nanoconjugate in the delivery of small interference and short-hairpin ribonucleic acid

Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown

The author has no competing conflicts of interest. 6